Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Opdivo + Yervoy significantly improved overall survival compared to lenvatinib or sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma in CheckMate -9DW trial – BMS

Written by | 10 Jun 2024

Bristol Myers Squibb announced the first presentation of results from the Phase III CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared… read more.

CheckMate-9DW trial evaluating Opdivo (nivolumab) + Yervoy (ipilimumab) meets primary endpoint of overall survival for the first-line treatment of advanced hepatocellular carcinoma – BMS

Written by | 24 Mar 2024

Bristol Myers Squibb announced the Phase III CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma (HCC) who… read more.

Hepatology publishes six-year data demonstrating improved clinical outcomes in patients with Alagille syndrome treated with Livmarli (maralixibat) – Mirum Pharma

Written by | 5 Mar 2024

Mirum Pharmaceuticals, Inc. announced that Hepatology published an analysis demonstrating a statistically significant improvement in six-year event-free and transplant-free survival in patients with Alagille syndrome (ALGS) treated with… read more.

Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

Written by | 11 Nov 2023

New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty… read more.

High drug price associated with decreased treatment retention for patients with chronic liver disease

Written by | 30 Aug 2023

Researchers from the University of Minnesota Medical School and College of Pharmacy have found that high costs for hepatic encephalopathy treatment in patients with end-stage liver disease were… read more.

FDA approval of Hepzato Kit for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma – Delcath Systems

Written by | 21 Aug 2023

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the FDA approved Hepzato Kit (melphalan/Hepatic Delivery… read more.

Sugar-sweetened drinks appear to raise risk of liver cancer and chronic liver disease in women

Written by | 13 Aug 2023

Postmenopausal women who consume one or more sugar sweetened beverage daily appear to have a significantly higher risk of developing liver cancer and chronic liver disease than women… read more.

Imfinzi + Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA phase III trial – AstraZeneca

Written by | 13 Jul 2023

Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for… read more.

FDA approves Bylvay for patients living with cholestatic pruritus due to Alagille syndrome – Ipsen

Written by | 24 Jun 2023

Ipsen announced that the FDA has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS). Bylvay is… read more.

New analysis of trial of semaglutide in adolescents shows it can reduce liver enzymes indicative of liver damage

Written by | 21 May 2023

A new substudy of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) shows that adolescents using semaglutide experienced significant… read more.

For NASH, bariatric surgery is more effective than drug treatment or lifestyle intervention

Written by | 25 Apr 2023

Bariatric surgery treats advanced non-alcoholic fatty liver disease (NASH) significantly more effectively than drug or lifestyle intervention, researchers reported on April 20, 2023 in The Lancet. Professor Francesco… read more.

Surgery most effective treatment of metabolic liver disease

Written by | 24 Apr 2023

Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease. A new paper, published today in The Lancet… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.